{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:50:42Z","timestamp":1794959442262,"version":"4.9.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Real-life data consist of exhaustive data which are not subject to selection bias. These data enable to study drug-safety profiles but are underused because of their temporality, necessitating complex models (i.e., safety depends on the dose, timing, and duration of treatment). We aimed to create a data-driven pipeline strategy that manages the complex temporality of real-life data to highlight the safety profile of a given drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We proposed to apply the weighted cumulative exposure (WCE) statistical model to all health events occurring after a drug introduction (in this paper HCQ) and performed bootstrap to select relevant diagnoses, drugs and interventions which could reflect an adverse drug reactions (ADRs). We applied this data-driven pipeline on a French national medico-administrative database to extract the safety profile of hydroxychloroquine (HCQ) from a cohort of 2,010 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proposed method selected eight drugs (metopimazine, anethole trithione, tropicamide, alendronic acid &amp; colecalciferol, hydrocortisone, chlormadinone, valsartan and tixocortol), twelve procedures (six ophthalmic procedures, two dental procedures, two skin lesions procedures and osteodensitometry procedure) and two medical diagnoses (systemic lupus erythematous, unspecified and discoid lupus erythematous) to be significantly associated with HCQ exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We provide a method extracting the broad spectrum of diagnoses, drugs and interventions associated to any given drug, potentially highlighting ADRs. Applied to hydroxychloroquine, this method extracted among others already known ADRs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12874-022-01628-3","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:02:49Z","timestamp":1654646569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A data-driven pipeline to extract potential adverse drug reactions through prescription, procedures and medical diagnoses analysis: application to a cohort study of 2,010 patients taking hydroxychloroquine with an 11-year follow-up"],"prefix":"10.1186","volume":"22","author":[{"given":"P.","family":"Sabatier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pouchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Danchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AS.","family":"Jannot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"15","key":"1628_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200\u20135. https:\/\/doi.org\/10.1001\/jama.279.15.1200.","journal-title":"JAMA"},{"key":"1628_CR2","unstructured":"La surconsommation de m\u00e9dicaments, un probl\u00e8me de sant\u00e9 publique,Question \u00e9crite n\u00b0 09333 de M. Philippe Dallier, S\u00e9nat - 13e l\u00e9gislature, publi\u00e9e dans le JO S\u00e9nat du 02\/07\/2009 - page 1653, https:\/\/www.senat.fr\/questions\/base\/2009\/qSEQ090709333.html."},{"issue":"1","key":"1628_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/0253-7613.150344","volume":"47","author":"VR Tandon","year":"2015","unstructured":"Tandon VR, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian J Pharmacol. 2015;47(1):65\u201371. https:\/\/doi.org\/10.4103\/0253-7613.150344.","journal-title":"Indian J Pharmacol"},{"issue":"7","key":"1628_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","volume":"16","author":"YM Alatawi","year":"2017","unstructured":"Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16(7):761\u20137. https:\/\/doi.org\/10.1080\/14740338.2017.1323867.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1628_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323\u201337. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.10.012.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1628_CR6","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10618-009-0152-3","volume":"20","author":"GN Nor\u00e9n","year":"2010","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361\u201387. https:\/\/doi.org\/10.1007\/s10618-009-0152-3.","journal-title":"Data Min Knowl Discov"},{"issue":"1","key":"1628_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0962280211403602","volume":"22","author":"I Zorych","year":"2013","unstructured":"Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39\u201356. https:\/\/doi.org\/10.1177\/0962280211403602.","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"1628_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/pds.2151","volume":"20","author":"GN Nor\u00e9n","year":"2011","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A, Edwards IR. Safety surveillance of longitudinal databases: methodological considerations. Pharmacoepidemiol Drug Saf. 2011;20(7):714\u20137. https:\/\/doi.org\/10.1002\/pds.2151.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1628_CR9","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/MLR.0b013e31825f63bf","volume":"50","author":"MJ Schuemie","year":"2012","unstructured":"Schuemie MJ, Coloma PM, Straatman H, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890\u20137. https:\/\/doi.org\/10.1097\/MLR.0b013e31825f63bf.","journal-title":"Med Care"},{"issue":"6","key":"1628_CR10","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","volume":"91","author":"R Harpaz","year":"2012","unstructured":"Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel Data Mining Methodologies for Adverse Drug Event Discovery and Analysis. Clin Pharmacol Ther. 2012;91(6):1010\u201321. https:\/\/doi.org\/10.1038\/clpt.2012.50.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"1628_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.3423","volume":"22","author":"M Kulldorff","year":"2013","unstructured":"Kulldorff M, Dashevsky I, Avery TR, et al. Drug safety data mining with a tree-based scan statistic: TREE-BASED SCAN STATISTIC DATA MINING METHOD. Pharmacoepidemiol Drug Saf. 2013;22(5):517\u201323. https:\/\/doi.org\/10.1002\/pds.3423.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1628_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1109\/TITB.2011.2165727","volume":"15","author":"E Chazard","year":"2011","unstructured":"Chazard E, Ficheur G, Bernonville S, Luyckx M, Beuscart R. Data mining to generate adverse drug events detection rules. IEEE Trans Inf Technol Biomed Publ IEEE Eng Med Biol Soc. 2011;15(6):823\u201330. https:\/\/doi.org\/10.1109\/TITB.2011.2165727.","journal-title":"IEEE Trans Inf Technol Biomed Publ IEEE Eng Med Biol Soc"},{"issue":"9296","key":"1628_CR13","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/S0140-6736(01)06898-2","volume":"358","author":"E Heeley","year":"2001","unstructured":"Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet Lond Engl. 2001;358(9296):1872\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(01)06898-2.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"1628_CR14","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396. https:\/\/doi.org\/10.2165\/00002018-200629050-00003.","journal-title":"Drug Saf"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"101839","DOI":"10.1016\/j.artmed.2020.101839","volume":"104","author":"C Zhan","year":"2020","unstructured":"Zhan C, Roughead E, Liu L, Pratt N, Li J. Detecting potential signals of adverse drug events from prescription data. Artif Intell Med. 2020;104:101839. https:\/\/doi.org\/10.1016\/j.artmed.2020.101839.","journal-title":"Artif Intell Med"},{"issue":"6","key":"1628_CR16","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1177\/0962280214527531","volume":"25","author":"MJ Schuemie","year":"2016","unstructured":"Schuemie MJ, Trifir\u00f2 G, Coloma PM, Ryan PB, Madigan D. Detecting adverse drug reactions following long-term exposure in longitudinal observational data: The exposure-adjusted self-controlled case series. Stat Methods Med Res. 2016;25(6):2577\u201392. https:\/\/doi.org\/10.1177\/0962280214527531.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"1628_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jclinepi.2005.01.021","volume":"59","author":"M Abrahamowicz","year":"2006","unstructured":"Abrahamowicz M, Bartlett G, Tamblyn R, du Berger R. Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J Clin Epidemiol. 2006;59(4):393\u2013403. https:\/\/doi.org\/10.1016\/j.jclinepi.2005.01.021.","journal-title":"J Clin Epidemiol"},{"issue":"27","key":"1628_CR18","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1002\/sim.3701","volume":"28","author":"MP Sylvestre","year":"2009","unstructured":"Sylvestre MP, Abrahamowicz M. Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med. 2009;28(27):3437\u201353. https:\/\/doi.org\/10.1002\/sim.3701.","journal-title":"Stat Med"},{"issue":"11\u201312","key":"1628_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/sim.4343","volume":"31","author":"M Abrahamowicz","year":"2012","unstructured":"Abrahamowicz M, Beauchamp ME, Sylvestre MP. Comparison of alternative models for linking drug exposure with adverse effects. Stat Med. 2012;31(11\u201312):1014\u201330. https:\/\/doi.org\/10.1002\/sim.4343.","journal-title":"Stat Med"},{"key":"1628_CR20","unstructured":"Sylvestre MP, Beauchamp ME, Abrahamowicz M. WCE package: weighted cumulative exposure models. CRAN. Published online August 8, 2018. https:\/\/cran.r-project.org\/web\/packages\/WCE\/vignettes\/WCE.pdf."},{"key":"1628_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jclinepi.2016.02.025","volume":"76","author":"D Yu","year":"2016","unstructured":"Yu D, Peat G, Bedson J, Edwards JJ, Turkiewicz A, Jordan KP. Weighted cumulative exposure models helped identify an association between early knee-pain consultations and future knee OA diagnosis. J Clin Epidemiol. 2016;76:218\u201328. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.02.025.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1628_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","volume":"133","author":"M Maclure","year":"1991","unstructured":"Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144\u201353. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a115853.","journal-title":"Am J Epidemiol"},{"key":"1628_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev.publhealth.21.1.193","volume":"21","author":"M Maclure","year":"2000","unstructured":"Maclure M, Mittleman MA. Should we use a case-crossover design? Annu Rev Public Health. 2000;21:193\u2013221. https:\/\/doi.org\/10.1146\/annurev.publhealth.21.1.193.","journal-title":"Annu Rev Public Health"},{"issue":"8","key":"1628_CR24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954\u201362. https:\/\/doi.org\/10.1002\/pds.4233.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1628_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","volume":"36","author":"G Moulis","year":"2015","unstructured":"Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases: What interest for medical research? Rev Med Interne. 2015;36(6):411\u20137. https:\/\/doi.org\/10.1016\/j.revmed.2014.11.009.","journal-title":"Rev Med Interne"},{"issue":"4","key":"1628_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","volume":"58","author":"P Tuppin","year":"2010","unstructured":"Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merli\u00e8re Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58(4):286\u201390. https:\/\/doi.org\/10.1016\/j.respe.2010.04.005.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"8","key":"1628_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s40264-020-00940-5","volume":"43","author":"CE King","year":"2020","unstructured":"King CE, Pratt NL, Craig N, et al. Detecting Medicine Safety Signals Using Prescription Sequence Symmetry Analysis of a National Prescribing Data Set. Drug Saf. 2020;43(8):787\u201395. https:\/\/doi.org\/10.1007\/s40264-020-00940-5.","journal-title":"Drug Saf"},{"issue":"22","key":"1628_CR28","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/sim.8215","volume":"38","author":"MJ Schuemie","year":"2019","unstructured":"Schuemie MJ, Ryan PB, Man KKC, Wong ICK, Suchard MA, Hripcsak G. A plea to stop using the case-control design in retrospective database studies. Stat Med. 2019;38(22):4199\u2013208. https:\/\/doi.org\/10.1002\/sim.8215.","journal-title":"Stat Med"},{"issue":"1","key":"1628_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/bja\/aet290","volume":"112","author":"GN Okoli","year":"2014","unstructured":"Okoli GN, Sanders RD, Myles P. Demystifying propensity scores. BJA Br J Anaesth. 2014;112(1):13\u20135. https:\/\/doi.org\/10.1093\/bja\/aet290.","journal-title":"BJA Br J Anaesth"},{"issue":"9","key":"1628_CR30","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/bcp.13291","volume":"83","author":"P Blin","year":"2017","unstructured":"Blin P, Dureau-Pournin C, Lassalle R, et al. Outcomes in patients after myocardial infarction similar to those of the PEGASUS-TIMI 54 trial: A cohort study in the French national claims database: Long-term post-MI outcomes. Br J Clin Pharmacol. 2017;83(9):2056\u201365. https:\/\/doi.org\/10.1111\/bcp.13291.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1628_CR31","doi-asserted-by":"publisher","first-page":"e001064","DOI":"10.1136\/rmdopen-2019-001064","volume":"5","author":"P Brito-Zer\u00f3n","year":"2019","unstructured":"Brito-Zer\u00f3n P, Retamozo S, Kostov B, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome. RMD Open. 2019;5(2):e001064. https:\/\/doi.org\/10.1136\/rmdopen-2019-001064.","journal-title":"RMD Open"},{"issue":"3","key":"1628_CR32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematous and\/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476\u201385. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209770.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1628_CR33","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annder.2015.07.015","volume":"143","author":"G Guettrot-Imbert","year":"2016","unstructured":"Guettrot-Imbert G, Morel N, Le Guern V, Plu-Bureau G, Frances C, Costedoat-Chalumeau N. Pregnancy and contraception in systemic and cutaneous lupus erythematous. Ann Dermatol Venereol. 2016;143(10):590\u2013600. https:\/\/doi.org\/10.1016\/j.annder.2015.07.015.","journal-title":"Ann Dermatol Venereol"},{"issue":"11","key":"1628_CR34","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1111\/1756-185X.13928","volume":"23","author":"W Wongtrakul","year":"2020","unstructured":"Wongtrakul W, Charoenngam N, Ponvilawan B, Ungprasert P. Allergic rhinitis and risk of systemic lupus erythematous: A systematic review and meta-analysis. Int J Rheum Dis. 2020;23(11):1460\u20137. https:\/\/doi.org\/10.1111\/1756-185X.13928.","journal-title":"Int J Rheum Dis"},{"issue":"11 Pt 1","key":"1628_CR35","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.lpm.2019.09.050","volume":"48","author":"C Mounier-Vehier","year":"2019","unstructured":"Mounier-Vehier C, Madika AL. Post-menopausal hypertension: Detecting, treating, accompany, prevent. Presse Medicale Paris Fr 1983. 2019;48(11 Pt 1):1288\u201394. https:\/\/doi.org\/10.1016\/j.lpm.2019.09.050.","journal-title":"Presse Medicale Paris Fr 1983"},{"issue":"2","key":"1628_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.rdc.2016.12.011","volume":"43","author":"M Talsania","year":"2017","unstructured":"Talsania M, Scofield RH. Menopause and Rheumatic Disease. Rheum Dis Clin North Am. 2017;43(2):287\u2013302. https:\/\/doi.org\/10.1016\/j.rdc.2016.12.011.","journal-title":"Rheum Dis Clin North Am"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-022-01628-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-022-01628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:02:52Z","timestamp":1654646572000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-022-01628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1186\/s12874-022-01628-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.14.21255406","asserted-by":"object"}]},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"166"}}